top of page

FEATURING

JTC_VI_Webcast_CYTH.png

Alzheimer's Disease
Spotlight 

Alzheimer's Icon_edited.png

TUESDAY APRIL 5th  1:00PM ET

Join us for an in-depth discussion about Alzheimer’s Disease, the unmet need and how Cyclo Therapeutics is working to advance a treatment.  

Featured Speaker:

Lemere-400x520[55].jpg

Cynthia A. Lemere, Ph.D.

Distinguished scientist who currently serves in the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital (BWH) and as Associate Professor of Neurology at Harvard Medical School in Boston

Members of Management:

CYTH_Scott_Fine_800px.png

N. Scott Fine

Chief Executive Officer, Cyclo Therapeutics

Lise_Lund_Kjems_400x520.png

Lise Lund Kjems, MD, Ph.D.

Chief Medical Officer, Cyclo Therapeutics

About Cyclo Therapeutics:

Cyclo Therapeutics, Inc. is a late clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease.

The Company’s Trappsol®â€¯Cyclo™, an orphan drug designated product in the United States and Europe, is being studied in a Phase 3 pivotal clinical trial for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning a Phase 2 clinical trial using Trappsol®â€¯Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol®â€¯Cyclo™ are in development.

For additional information, visit the Company’s website: www.cyclotherapeutics.com. 

bottom of page